Dundee Corp T.DC.A

Update on TauRx website

[pierrelebel]

TauRx continues to liaise with both the Medicines and Healthcare products Regulatory Agency (MHRA) and National Institute for Health and Care Excellence (NICE) regarding the company’s UK Marketing Authorisation Application (MAA) for hydromethylthionine mesylate (HMTM), a 4 mg oral tablet for the treatment of mild cognitive impairment (MCI-AD) and mild to moderate Alzheimer’s disease.

As is standard, we have received a request for further information from the MHRA, and a company response is due to be submitted in late February 2025.

We welcome the flexibility and commitment shown by the MHRA and NICE to process our application, and we will continue to work with them to address one of the world’s greatest unmet medical needs.

A paper reporting the latest Phase 3 trial of HMTM is currently undergoing peer review. The results from earlier trials have been previously reported in peer-reviewed publications, and these have been consistent in showing clinically meaningful therapeutic activity on cognitive decline and brain shrinkage.

LINK

[FrozenInOntario]

Pierre, Thanks for this link.  This is why these boards were made for.   So a delay of a couple of months. Thanks again,

[TheCount11]

Thanks for sharing! In the spirit of sharing this might be of interest https://www.gov.uk/government/news/mhra-approves-new-diagnostic-agent-for-adult-patients-showing-signs-of-cognitive-impairment-for-alzheimers-disease#:~:text=Press%20release-,MHRA%20approves%20new%20diagnostic%20agent%20for%20adult%20patients%20showing%20signs,brain%20scan%20called%20a%20PET

[TheCount11]

https://www.bloomberg.com/news/videos/2024-03-06/novartis-ceo-on-next-gen-alzheimer-cancer-therapies. Note: Exelon patch has been around for 15 years.  I am not a doctor so won't pontificate cholinesterase inhibitors only treating the symptoms...